Stock Report

All about this stock under one free report Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Amryt Pharma plc (AMYT)

Stock Card factsheet share-fund-plan-icon

$14.70

$0.00 (0.00%)

As on 21-Apr-2023 09:30EDT

Market cap

info icon

$943 Mln

Revenue (TTM)

info icon

$244 Mln

P/E Ratio

info icon

39.7

P/B Ratio

info icon

1.4

Div. Yield

info icon

0 %

Amryt Pharma (AMYT) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 14.70 High: 14.70

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-20 Mln

  • ROEROE information

    -0 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    28.71

  • EV/EBITDAEV/EBITDA information

    6.6

  • Debt to EquityDebt to Equity information

    0.6

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-0.2

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    64,133,900

10 Years Aggregate

CFO

€-37.62 Mln

EBITDA

€-105.25 Mln

Net Profit

€-301.70 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Amryt Pharma (AMYT)
101.4 0.9 0.2 94.4 -- -- --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 21-Apr-2023  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2022
2021
Amryt Pharma (AMYT)
-32.4 -23.7
S&P Small-Cap 600
-17.4 25.3
BSE Sensex
4.4 22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in (€ Mln)

Annual

*All values are in (€ Mln)

Annual

*All values are in (€ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Amryt Pharma (AMYT)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct...  to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.  Read more

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Amryt Pharma (AMYT)

The share price of Amryt Pharma plc (AMYT) is $14.70 (NASDAQ) as of 21-Apr-2023 09:30 EDT. Amryt Pharma plc (AMYT) has given a return of 94.44% in the last 1 years.

The P/E ratio of Amryt Pharma plc (AMYT) is 39.73 times as on 21-Apr-2023, a 38 premium to its peers’ median range of 28.71 times.
The P/B ratio of Amryt Pharma plc (AMYT) is 1.40 times as on 21-Apr-2023, a 77 discount to its peers’ median range of 6.00 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2021
-29.12
1.57
2020
-4.33
6.85
2019
--
--
2018
--
--
2017
--
--

The 52-week high and low of Amryt Pharma plc (AMYT) are Rs -- and Rs -- as of 17-May-2026.

Amryt Pharma plc (AMYT) has a market capitalisation of $ 943 Mln as on 21-Apr-2023. As per SEBI classification, it is a Small Cap company.

Before investing in Amryt Pharma plc (AMYT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.